{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:55:06Z","timestamp":1791309306188,"version":"4.3.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ijpharm.2019.04.047","type":"journal-article","created":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T01:33:11Z","timestamp":1555723991000},"page":"329-339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["Nose-to-brain delivery of levetiracetam after intranasal administration to mice"],"prefix":"10.1016","volume":"564","author":[{"given":"Joana","family":"Gon\u00e7alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Bicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Liberal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui Caetano","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3854-6549","authenticated-orcid":false,"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijpharm.2019.04.047_b0005","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/NDT.S2937","article-title":"Levetiracetam in the treatment of epilepsy","volume":"4","author":"Abou-Khalil","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.ijpharm.2019.04.047_b0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","article-title":"Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs","volume":"281","author":"Agrawal","year":"2018","journal-title":"J. Controlled Release"},{"issue":"1","key":"10.1016\/j.ijpharm.2019.04.047_b0015","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/FTD.0000000000000470","article-title":"Influence of comedication on levetiracetam pharmacokinetics","volume":"40","author":"Aldaz","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ijpharm.2019.04.047_b9000","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1208\/s12249-010-9477-x","article-title":"Development and characterization of mucoadhesive in situ nasal gel of mdazolam prepared with ficus carica mucilage","volume":"11","author":"Basu","year":"2010","journal-title":"AAPS Pharm. Sci. Tech."},{"issue":"4","key":"10.1016\/j.ijpharm.2019.04.047_b0020","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40263-017-0424-1","article-title":"Newer antiepileptic drugs in status epilepticus: prescription trends and outcomes in comparison with traditional agents","volume":"31","author":"Beuchat","year":"2017","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.ijpharm.2019.04.047_b0025","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40263-018-0509-5","article-title":"Newer antiepileptic drugs for status epilepticus in adults: what's the evidence?","volume":"32","author":"Beuchat","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ijpharm.2019.04.047_b0030","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.yebeh.2018.03.033","article-title":"Psychiatric comedication in patients with epilepsy","volume":"83","author":"Bosak","year":"2018","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.ijpharm.2019.04.047_b0035","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ejpb.2018.05.009","article-title":"Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics","volume":"128","author":"Bourganis","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2019.04.047_b0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eplepsyres.2018.07.008","article-title":"In vitro and in vivo experimental models employed in the discovery and development of antiepileptic drugs for pharmacoresistant epilepsy","volume":"146","author":"Campos","year":"2018","journal-title":"Epilepsy Res."},{"issue":"2","key":"10.1016\/j.ijpharm.2019.04.047_b0045","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/0023677216639470","article-title":"Directive 2010\/63\/EU: facilitating full and correct implementation","volume":"50","author":"Chlebus","year":"2016","journal-title":"Lab Anim."},{"key":"10.1016\/j.ijpharm.2019.04.047_b0050","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jconrel.2018.12.049","article-title":"Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis","volume":"295","author":"Costa","year":"2019","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.ijpharm.2019.04.047_b0055","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.ijpharm.2019.04.047_b0060","doi-asserted-by":"crossref","DOI":"10.1100\/2012\/126723","article-title":"Temperature-sensitive gels for intratumoral delivery of \u03b2-lapachone: effect of cyclodextrins and ethanol","volume":"2012","author":"Cunha-Filho","year":"2012","journal-title":"Sci. World J."},{"key":"10.1016\/j.ijpharm.2019.04.047_b0065","unstructured":"EMA, 2004. Keppra\u00ae European Public Assessment Report - Scientific discussion. Retrieved from www.ema.europa.eu\/documents\/scientific-discussion\/keppra-epar-scientific-discussion_en.pdf."},{"key":"10.1016\/j.ijpharm.2019.04.047_b0070","unstructured":"EMA, 2011. Guideline on bioanalytical method validation. Retrieved from https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf."},{"key":"10.1016\/j.ijpharm.2019.04.047_b0075","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eplepsyres.2017.11.015","article-title":"The new definition and classification of seizures and epilepsy","volume":"139","author":"Falco-Walter","year":"2018","journal-title":"Epilepsy Res."},{"issue":"1","key":"10.1016\/j.ijpharm.2019.04.047_b0080","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/10717544.2017.1357148","article-title":"Agomelatine-based in situ gels for brain targeting via the nasal route: statistical optimization, in vitro, and in vivo evaluation","volume":"24","author":"Fatouh","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ijpharm.2019.04.047_b0085","unstructured":"FDA, 2018. Bioanalytical Method Validation Guidance for Industry. Retrieved from https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm070107.pdf."},{"issue":"5","key":"10.1016\/j.ijpharm.2019.04.047_b0090","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.drudis.2018.01.005","article-title":"An update on the role of nanovehicles in nose-to-brain drug delivery","volume":"23","author":"Feng","year":"2018","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.ijpharm.2019.04.047_b0095","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejpb.2014.03.004","article-title":"Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules","volume":"88","author":"Fortuna","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2019.04.047_b0100","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3389\/fneur.2018.01067","article-title":"Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs","volume":"9","author":"Galgani","year":"2018","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.ijpharm.2019.04.047_b0105","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4155\/bio-2017-0199","article-title":"Development and full validation of an innovative HPLC-diode array detection technique to simultaneously quantify lacosamide, levetiracetam and zonisamide in human plasma","volume":"10","author":"Goncalves","year":"2018","journal-title":"Bioanalysis"},{"issue":"Pt B","key":"10.1016\/j.ijpharm.2019.04.047_b0110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.neuropharm.2018.06.006","article-title":"Intranasal administration of progesterone: a potential efficient route of delivery for cerebroprotection after acute brain injuries","volume":"145","author":"Guennoun","year":"2019","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.ijpharm.2019.04.047_b0115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.carbpol.2012.02.051","article-title":"Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation","volume":"89","author":"Haque","year":"2012","journal-title":"Carbohydr. Polym."},{"issue":"1s","key":"10.1016\/j.ijpharm.2019.04.047_b0120","doi-asserted-by":"crossref","first-page":"149s","DOI":"10.18433\/jpps30081","article-title":"Therapeutic drug monitoring of levetiracetam in select populations","volume":"21","author":"Jarvie","year":"2018","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.ijpharm.2019.04.047_b0125","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FTD.0b013e31825ee389","article-title":"Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication","volume":"34","author":"Johannessen Landmark","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ijpharm.2019.04.047_b0130","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.schres.2016.11.027","article-title":"Intranasal delivery of antipsychotic drugs","volume":"184","author":"Katare","year":"2017","journal-title":"Schizophr Res."},{"issue":"6","key":"10.1016\/j.ijpharm.2019.04.047_b0135","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.ijpharm.2019.04.047_b0140","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yebeh.2014.05.031","article-title":"The consequences of refractory epilepsy and its treatment","volume":"37","author":"Laxer","year":"2014","journal-title":"Epilepsy Behav."},{"issue":"Suppl 5","key":"10.1016\/j.ijpharm.2019.04.047_b0145","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1528-1167.2007.01302.x","article-title":"ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy","volume":"48","author":"Lazarowski","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.ijpharm.2019.04.047_b0150","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.yebeh.2018.01.001","article-title":"Efficacy and tolerability of perampanel and levetiracetam as first add-on therapy in patients with epilepsy: a retrospective single center study","volume":"80","author":"Liguori","year":"2018","journal-title":"Epilepsy Behav."},{"issue":"1","key":"10.1016\/j.ijpharm.2019.04.047_b0155","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/14767058.2014.986651","article-title":"The treatment of neonatal seizures: focus on Levetiracetam","volume":"29","author":"Loiacono","year":"2016","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"10.1016\/j.ijpharm.2019.04.047_b0160","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eplepsyres.2016.05.016","article-title":"Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies","volume":"126","author":"Loscher","year":"2016","journal-title":"Epilepsy Res."},{"issue":"7","key":"10.1016\/j.ijpharm.2019.04.047_b0165","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s11064-017-2222-z","article-title":"Animal models of seizures and epilepsy: past, present, and future role for the discovery of antiseizure drugs","volume":"42","author":"Loscher","year":"2017","journal-title":"Neurochem. Res."},{"issue":"7","key":"10.1016\/j.ijpharm.2019.04.047_b0170","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1007\/s11064-016-2025-7","article-title":"The search for new screening models of pharmacoresistant epilepsy: is induction of acute seizures in epileptic rodents a suitable approach?","volume":"42","author":"Loscher","year":"2017","journal-title":"Neurochem. Res."},{"issue":"1","key":"10.1016\/j.ijpharm.2019.04.047_b0175","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1055\/s-0037-1608653","article-title":"A systematic review of the efficacy of levetiracetam in neonatal seizures","volume":"49","author":"McHugh","year":"2018","journal-title":"Neuropediatrics"},{"issue":"2","key":"10.1016\/j.ijpharm.2019.04.047_b0180","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/10717544.2013.838713","article-title":"Insights into direct nose to brain delivery: current status and future perspective","volume":"21","author":"Mittal","year":"2014","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.ijpharm.2019.04.047_b0185","doi-asserted-by":"crossref","first-page":"1313676","DOI":"10.1080\/20010001.2017.1313676","article-title":"Guidelines for collection and processing of lungs from aged mice for histological studies","volume":"7","author":"Morton","year":"2017","journal-title":"Pathobiol. Aging Age Relat. Dis."},{"issue":"17","key":"10.1016\/j.ijpharm.2019.04.047_b0190","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1046\/j.1432-1327.2000.01606.x","article-title":"Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity","volume":"267","author":"O'Brien","year":"2000","journal-title":"Eur. J. Biochem."},{"issue":"3","key":"10.1016\/j.ijpharm.2019.04.047_b0195","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/ilar\/ilw029","article-title":"Protecting animals and enabling research in the european union: an overview of development and implementation of directive 2010\/63\/EU","volume":"57","author":"Olsson","year":"2016","journal-title":"ILAR J."},{"key":"10.1016\/j.ijpharm.2019.04.047_b0200","article-title":"Directive 2010\/63\/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes","author":"Parliament","year":"2010","journal-title":"Official J. Eur. Union"},{"issue":"3","key":"10.1016\/j.ijpharm.2019.04.047_b0205","doi-asserted-by":"crossref","first-page":"288","DOI":"10.18433\/J3NC79","article-title":"Intranasal drug delivery: how, why and what for?","volume":"12","author":"Pires","year":"2009","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2019.04.047_b0210","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2017.11.047","article-title":"Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies","volume":"270","author":"Pires","year":"2018","journal-title":"J. Controlled Release"},{"issue":"10","key":"10.1016\/j.ijpharm.2019.04.047_b0215","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2217\/pgs.10.126","article-title":"Transporter hypothesis of drug-resistant epilepsy: challenges for pharmacogenetic approaches","volume":"11","author":"Potschka","year":"2010","journal-title":"Pharmacogenomics"},{"issue":"10","key":"10.1016\/j.ijpharm.2019.04.047_b0220","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.etp.2015.08.002","article-title":"A simple method for the formalin fixation of lungs in toxicological pathology studies","volume":"67","author":"Qu","year":"2015","journal-title":"Exp. Toxicol. Pathol."},{"issue":"7 Suppl","key":"10.1016\/j.ijpharm.2019.04.047_b0225","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1177\/0192623309353423","article-title":"Proliferative and nonproliferative lesions of the rat and mouse respiratory tract","volume":"37","author":"Renne","year":"2009","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ijpharm.2019.04.047_b0230","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejps.2014.04.019","article-title":"Intranasal administration of carbamazepine to mice: a direct delivery pathway for brain targeting","volume":"60","author":"Serralheiro","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1\u20132","key":"10.1016\/j.ijpharm.2019.04.047_b0235","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijpharm.2015.05.021","article-title":"Direct nose-to-brain delivery of lamotrigine following intranasal administration to mice","volume":"490","author":"Serralheiro","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2019.04.047_b0240","doi-asserted-by":"crossref","unstructured":"Serralheiro, A. A., G.; Sousa, J.; Fortuna, A.; Falc\u00e3o, A. (2013). Nose as a route for drug delivery. In T. M. E. S. \u00d6nerci (Ed.), Nasal Physiology and Pathophysiology of Nasal Disorders. (pp. 191\u2013216).","DOI":"10.1007\/978-3-642-37250-6_15"},{"key":"10.1016\/j.ijpharm.2019.04.047_b0245","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.yebeh.2018.01.039","article-title":"Antiepileptic drug treatment of generalized tonic-clonic seizures: an evaluation of regulatory data and five criteria for drug selection","volume":"82","author":"Shorvon","year":"2018","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.ijpharm.2019.04.047_b0250","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.seizure.2018.09.004","article-title":"Review on the relevance of therapeutic drug monitoring of levetiracetam","volume":"62","author":"Sourbron","year":"2018","journal-title":"Seizure"},{"issue":"5","key":"10.1016\/j.ijpharm.2019.04.047_b0255","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.seizure.2014.02.003","article-title":"Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs)","volume":"23","author":"Stepanova","year":"2014","journal-title":"Seizure"},{"issue":"11","key":"10.1016\/j.ijpharm.2019.04.047_b0260","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s40262-017-0537-1","article-title":"Levetiracetam clinical pharmacokinetic monitoring in pediatric patients with epilepsy","volume":"56","author":"Tan","year":"2017","journal-title":"Clin. Pharmacokinet."},{"issue":"10","key":"10.1016\/j.ijpharm.2019.04.047_b0265","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s11051-013-1993-7","article-title":"Design of a dual nanostructured lipid carrier formulation based on physicochemical, rheological, and mechanical properties","volume":"15","author":"Vitorino","year":"2013","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.ijpharm.2019.04.047_b0270","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3389\/fneur.2013.00192","article-title":"Clinical pharmacology and pharmacokinetics of levetiracetam","volume":"4","author":"Wright","year":"2013","journal-title":"Front. Neurol."},{"issue":"10","key":"10.1016\/j.ijpharm.2019.04.047_b0275","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/17425247.2018.1517741","article-title":"In situ gelling and mucoadhesive polymers: why do they need each other?","volume":"15","author":"Zahir-Jouzdani","year":"2018","journal-title":"Expert Opin. Drug Deliv."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517319303102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517319303102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:40:50Z","timestamp":1759916450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517319303102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":56,"alternative-id":["S0378517319303102"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2019.04.047","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nose-to-brain delivery of levetiracetam after intranasal administration to mice","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2019.04.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}